The best way to lower drug prices: End the Medicaid program that blocks discounts

On January 31, the Trump Administration unveiled a long-awaited plan to outlaw controversial rebates that drugmakers pay to pharmacy benefit managers and plan sponsors that negotiate drug prices on behalf of federal programs. Those rebates are supposed to lower the prices that health plans charge their patients––and the Administration swears that the those tens in billions in cash aren’t benefiting folks who get their prescriptions filled at the corner pharmacy counters or delivered by mail.